TY - JOUR KW - Contingency management KW - drug- and alcohol-use biomarkers KW - novel substance-use treatment technologies KW - substance-use disorder treatment AU - S. M. McPherson AU - E. Burduli AU - C. L. Smith AU - J. Herron AU - O. Oluwoye AU - K. Hirchak AU - M. F. Orr AU - M. G. McDonell AU - J. M. Roll A1 - AB - This review of contingency management (CM; the behavior-modification method of providing reinforcement in exchange for objective evidence of a desired behavior) for the treatment of substance-use disorders (SUDs) begins by describing the origins of CM and how it has come to be most commonly used during the treatment of SUDs. Our core objective is to review, describe, and discuss three ongoing critical advancements in CM. We review key emerging areas wherein CM will likely have an impact. In total, we qualitatively reviewed 31 studies in a systematic fashion after searching PubMed and Google Scholar. We then describe and highlight CM investigations across three broad themes: adapting CM for underserved populations, CM with experimental technologies, and optimizing CM for personalized interventions. Technological innovations that allow for mobile delivery of reinforcers in exchange for objective evidence of a desired behavior will likely expand the possible applications of CM throughout the SUD-treatment domain and into therapeutically related areas (eg, serious mental illness). When this mobile technology is coupled with new, easy-to-utilize biomarkers, the adaptation for individual goal setting and delivery of CM-based SUD treatment in hard-to-reach places (eg, rural locations) can have a sustained impact on communities most affected by these disorders. In conclusion, there is still much to be done, not only technologically but also in convincing policy makers to adopt this well-established, cost-effective, and evidence-based method of behavior modification. AD - Department of Medical Education and Clinical Sciences, Elson S Floyd College of Medicine, Washington State University, sterling.mcpherson@wsu.edu.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Analytics and Psychopharmacology Laboratory (APPL), Washington State University, sterling.mcpherson@wsu.edu.; Translational Addictions Research Center, Washington State University, sterling.mcpherson@wsu.edu.; Department of Medical Education and Clinical Sciences, Elson S Floyd College of Medicine, Washington State University, sterling.mcpherson@wsu.edu.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Analytics and Psychopharmacology Laboratory (APPL), Washington State University, sterling.mcpherson@wsu.edu.; Translational Addictions Research Center, Washington State University, sterling.mcpherson@wsu.edu.; College of Nursing, Washington State University.; Department of Medical Education and Clinical Sciences, Elson S Floyd College of Medicine, Washington State University, sterling.mcpherson@wsu.edu.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Analytics and Psychopharmacology Laboratory (APPL), Washington State University, sterling.mcpherson@wsu.edu.; Translational Addictions Research Center, Washington State University, sterling.mcpherson@wsu.edu.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Behavioral Health Interventions (BHI), Washington State University, Spokane, WA, USA.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Behavioral Health Interventions (BHI), Washington State University, Spokane, WA, USA.; Programs of Excellence in Addictions Research, Washington State University, sterling.mcpherson@wsu.edu.; Analytics and Psychopharmacology Laboratory (APPL), Washingto(TRUNCATED) BT - Substance abuse and rehabilitation C5 - Opioids & Substance Use; Healthcare Disparities DO - 10.2147/SAR.S138439 JF - Substance abuse and rehabilitation LA - eng M1 - Journal Article N2 - This review of contingency management (CM; the behavior-modification method of providing reinforcement in exchange for objective evidence of a desired behavior) for the treatment of substance-use disorders (SUDs) begins by describing the origins of CM and how it has come to be most commonly used during the treatment of SUDs. Our core objective is to review, describe, and discuss three ongoing critical advancements in CM. We review key emerging areas wherein CM will likely have an impact. In total, we qualitatively reviewed 31 studies in a systematic fashion after searching PubMed and Google Scholar. We then describe and highlight CM investigations across three broad themes: adapting CM for underserved populations, CM with experimental technologies, and optimizing CM for personalized interventions. Technological innovations that allow for mobile delivery of reinforcers in exchange for objective evidence of a desired behavior will likely expand the possible applications of CM throughout the SUD-treatment domain and into therapeutically related areas (eg, serious mental illness). When this mobile technology is coupled with new, easy-to-utilize biomarkers, the adaptation for individual goal setting and delivery of CM-based SUD treatment in hard-to-reach places (eg, rural locations) can have a sustained impact on communities most affected by these disorders. In conclusion, there is still much to be done, not only technologically but also in convincing policy makers to adopt this well-established, cost-effective, and evidence-based method of behavior modification. PY - 2018 SN - 1179-8467; 1179-8467; 1179-8467 SP - 43 EP - 57 EP - T1 - A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies T2 - Substance abuse and rehabilitation TI - A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies U1 - Opioids & Substance Use; Healthcare Disparities U2 - 30147392 U3 - 10.2147/SAR.S138439 VL - 9 VO - 1179-8467; 1179-8467; 1179-8467 Y1 - 2018 Y2 - Aug 13 ER -